TAK
TAK
US8740602052
Takeda Pharmaceutical Company L
Loading chart...
Solid Quality Asset with Moderate Fluctuation

Healthy balance: Exemplary business financials (Health Score: 60/100) paired with moderate price swings for a single equity (±19.3% p.a.). The score (5/7) reflects the standard baseline for equities under SRI rules.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
5/7 Elevated
5 / 7 SRI Price Fluctuation & Beta

Above-average volatility. Suitable for experienced investors with high risk tolerance (5+ years horizon). Moves noticeably less than the broader market (0.1x).

Beta (Market Relation)
0.1x
Defensive
Volatility (5Y p.a.)
19.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-26.4%
5-Year Horizon
Sharpe Ratio
0.15
Return / Risk
Elevated Risk / Growth: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +29.4%
3 Years 19.9% -20.1% 0.21 +6.7%
5 Years 19.3% -26.4% 0.15 +5.4%
10 Years 23.1% -59.6% -0.21 -2.5%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Historical Stress Test: Maximum peak-to-trough drawdown of -59.6% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
1.92
ende